Baxter International Inc.
) recently presented clinical data supporting the safety and
efficacy of its VIVIA Haemodialysis (HD) System, designed to
deliver High Dose HD in the home environment. Following the
release, shares of BAX, however, dropped by a marginal 0.1% to
close at $73.64 yesterday.
BAX shared its VIVIA HD system data for the first time with the
European nephrology community at the 51st Congress of the European
Renal Association and European Dialysis and Transplant Association
(ERA-EDTA), which took place from May 31 to Jun 3 in Amsterdam.
VIVIA HD System
The VIVIA HD System is designed to support High Dose HD therapy - a
more frequent and extended duration treatment administered in the
form of short daily treatments or nocturnal treatments.
The VIVIA HD System's user-friendly features allow a greater number
of haemodailysis patients to access High Dose HD therapy in their
home environment. The system also includes a fully integrated
wireless connectivity platform that allows physicians to
comprehensively monitor home therapy remotely.
The VIVIA HD System received CE Mark approval for a European launch
in Dec 2013. Year-to-date, the system is being introduced on a
limited basis in select European dialysis clinics. BAX plans to
expand the launch to other European countries in 2015.
VIVIA Clinical Studies
The first in-human study was a prospective, single arm clinical
study conducted in haemodialysis centers in the U.S. Under the
study, 22 patients received four HD treatments with the VIVIA HD
system every week for 10 weeks.
In the second prospective, single arm clinical study carried out in
haemodialysis centres in Canada, 17 patients received nocturnal HD
treatments with the VIVIA HD system 3 times a week for 6 weeks.
Results from both the studies demonstrated the system's capability
to accurately remove excess body fluid, as shown by a strong
correlation established between fluid weights removed and weight
change. The research further confirmed the system's ability to
clear uremic toxins safely and reliably.
Apart from its clinical advantages, additional data presented at
the congress holds the VIVIA HD System as a potentially more
sustainable and cost-effective therapy.
Results from another study established that the VIVIA HD System
emitted the lowest amount of carbon compared to a
currently-available home HD device and a conventional in-centre HD
device that can be used for home dialysis. By means of a lower
carbon footprint, the system is set to make a significant impact in
delivering sustainable HD therapies.
Furthermore, other studies found High Dose HD at home to be cost
effective when compared with conventional in-centre HD devices. Two
separate analyses of High Dose HD in the U.K. confirmed that
increased usage could lead to considerable cost savings and an
increase in quality-adjusted, life-years gained.
Currently, BAX retains a Zacks Rank #3 (Hold). Some better-ranked
medical product stocks worth considering are
Eagle Pharmaceuticals Inc.
). All these stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
BAXTER INTL (BAX): Free Stock Analysis Report
EAGLE PHARMACT (EGRX): Free Stock Analysis
NEUROMETRIX INC (NURO): Free Stock Analysis
CARDICA INC (CRDC): Free Stock Analysis Report
To read this article on Zacks.com click here.